Delving into the Latest Updates on Beijing Kangming Hanghui Biotechnology Co Ltd. with Synapse

Overview

Tags

Neoplasms

Skin and Musculoskeletal Diseases

Small molecule drug

Disease domain score

A glimpse into the focused therapeutic areas

Technology Platform

Most used technologies in drug development

Targets

Most frequently developed targets

Disease Domain	Count

Neoplasms	1

Top 5 Drug Type	Count

Small molecule drug	1

Top 5 Target	Count

HSP90B1(heat shock protein 90 beta family member 1)	1

主要目的：（1）评价注射用KMHH-03在晚期乳腺癌受试者中的安全性及耐受性；（2）确定注射用KMHH-03单次给药的剂量限制性毒性（DLT）与最大耐受剂量（MTD）。次要目的：（1）评价注射用KMHH-03在晚期乳腺癌受试者中的药代动力学（PK）特征；（2）评估注射用KMHH-03在晚期乳腺癌受试者中的免疫原性；（3）观察注射用KMHH-03在晚期乳腺癌受试者中的初步疗效，为后续临床试验推荐剂量和给药方案提供依据。

[Translation]

Primary objectives: (1) To evaluate the safety and tolerability of KMHH-03 for injection in subjects with advanced breast cancer; (2) To determine the dose-limiting toxicity (DLT) and maximum tolerated dose (MTD) of a single dose of KMHH-03 for injection. Secondary objectives: (1) To evaluate the pharmacokinetic (PK) characteristics of KMHH-03 for injection in subjects with advanced breast cancer; (2) To evaluate the immunogenicity of KMHH-03 for injection in subjects with advanced breast cancer; (3) To observe the preliminary efficacy of KMHH-03 for injection in subjects with advanced breast cancer and provide a basis for the recommended dose and dosing regimen for subsequent clinical trials.

Start Date11 Oct 2023

Sponsor / Collaborator

Beijing Kangming Hanghui Biotechnology Co Ltd.

100 Clinical Results associated with Beijing Kangming Hanghui Biotechnology Co Ltd.

Login to view more data

0 Patents (Medical) associated with Beijing Kangming Hanghui Biotechnology Co Ltd.

Login to view more data

100 Deals associated with Beijing Kangming Hanghui Biotechnology Co Ltd.

Login to view more data

100 Translational Medicine associated with Beijing Kangming Hanghui Biotechnology Co Ltd.

Login to view more data

Corporation Tree

Boost your research with our corporation tree data.

login

or

view full example data

Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 23 Nov 2024

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Phase 1 Clinical

1

Login to view more data